Prof. Dr. Paul W.H.I. Parren (30-4-1963; Professor in Molecular Immunology at the Leiden University Medical Center; owner at Sparring Bioconsult BV & former Scientific Director of Genmab) is an expert in biotechnology, translational science and drug development. He authored over 200 scientific publications that have a total of > 21,000 citations with an h factor of 77 (Google Scholar, accessed Jan. 31, 2018). He edited issues of Current Opinion in Immunology (2008 & 2016) and Methods (2014). He in inventor of 35 issued patent families that resulted in 44 US and 28 EU patents. He invented and developed the FDA/EMA-approved therapeutic antibodies ofatumumab (Arzerra) and daratumumab (DARZALEX), and the DuoBody and HexaBody technologies to generate bispecific and effector function-enhanced antibodies. Ofatumumab, daratumumab and teprotumumab, received FDA Breakthrough Therapy designations in 2013, 2015 and 2016 and eight further antibodies, including two ADCs and two bispecific antibodies, are in clinical development. Starting Dec. 1, 2017, Dr. Parren provides consulting services in the area of medical biotechnology including all aspects of therapeutic antibody development from discovery through (pre)-clinical development.